The proposal for an in vitro diagnostics (IVD) regulation currently under discussion in the European Parliament and Council of the European Union will chart the future of the regulatory system for IVDs in Europe.

March saw the publication of the latest innovation scoreboard. ‘More stats!’ I hear you groan, but this is important reading for researchers, businesses and governments in biotech. It tells you where the innovation leaders and followers are, as well as informing you about changes in performance over time.

The use of diagnostic testing is at the centre of Personalised Healthcare (PHC), not only for classifying a disease but also for determining which therapy will be most suitable for an individual patient or a stratified group of patients suffering from that disease. It is all about improving outcomes and tolerability.

The end of the FP7 process has been a busy one, with a rush to grab the last EC funds before we all get thirsty in the break between FP7 and the launch of Horizon 2020 in 2014.

In an era when Member States are doing their utmost to limit national exposure in the EU budget, making the right choices has become more crucial than ever before to shaping Europe’s future.

All the hard work I invested in 2012 to rescue the Eurozone with biotechnology has reaped a new reward in 2013, as the European Parliament and Council finally approved the European patent in December.

The revision of the EU Medical Devices Directives (MDD) could not have come at a more critical moment. The recent PIP breast implant incident has made it crystal clear that healthcare actors must pull together to ensure similar cases of fraud never happen again.

It’s getting a little boring listening to conversations about the 2014-2020 budget. As citizens, we’re subjected to endless national bickering and point-scoring as national leaders look to secure their own positions through sounding ‘tough on Europe’, as if the EU was a strange alien beast designed to steal their money and straighten all their bananas.

Partnering and even open innovation is becoming increasingly important for our industry in a world where health systems are undergoing profound transformations.

We all read with dismay but not a huge amount of surprise the October paper from French researchers led by Gilles-Eric Séralini on the two-year rat-feeding study looking at the effects of glyphosate-treated GM maize.